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Background: This study was designed to investigate the agreement of 2D transthoracic 
echocardiography (2D TTE) with cardiovascular magnetic resonance imaging (CMR) in a 
contemporary population of ST-elevation myocardial infarction (STEMI) patients.  
 
Methods: In this subanalysis of the GIPS-III trial, a randomized controlled trial investigating 
the administration of metformin in STEMI patients to prevent reperfusion injury, we studied 
259 patients who underwent same-day CMR and 2D TTE assessments four months after 
hospitalization for a first STEMI. Bland-Altman analyses were performed to assess agreement 
between LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), LV ejection 
fraction (LVEF), and LV mass measurements. Sensitivity and specificity of 2D TTE to detect 
categories of LVEF (≤35%, 35-50%, ≥50%) was determined. Linear regression of absolute 
differences in measurements between imaging modalities was used to investigate whether 
patient characteristics impact measurement bias. 
 
Results: Pairwise difference (bias) and 95% limits of agreement between CMR and 2D TTE 
measurements were +84 (37, 147) ml for LVEDV, +39 (6, 85) ml for LVESV, -1.1 ± 13.5% 
for LVEF, and -75 (-154, -14) g for LV mass. Sensitivity and specificity of 2D TTE to detect 
subjects with moderately depressed LVEF (35-50%) as measured by CMR were 52% and 
88% respectively. We observed a significant effect of enzymatic infarct size on bias between 
2D TTE and CMR in measuring LVESV and LVEF (P=0.029, P=0.001 respectively), of age 
and sex on bias between 2D TTE and CMR in measuring LV mass (P=0.027, P<0.001) and 
LVEDV (P=0.001, P=0.039), and of heart rate on bias between 2D TTE and CMR in LV 
volume measurements (P=0.004, P=0.016).  
 
Conclusions: Wide limits of agreement, underestimation of LV volumes and overestimation 
of LV mass was observed when comparing 2D TTE to CMR. Enzymatic infarct size, age, sex, 
and heart rate are potential sources of bias between imaging modalities. 
 
Highlights: 
 This study investigated bias between 2D TTE and CMR measurements in a large 





 2D TTE underestimates LV volumes and overestimates LVM when compared to 
CMR. 
 Enzymatic infarct size, age, sex, and heart rate are potential sources of bias between 
2D TTE and CMR-derived measurements. 
 
Keywords: Magnetic Resonance Imaging; 2D Transthoracic Echocardiography; Myocardial 
Infarction; Left Ventricular Function 
 
Abbreviations: 
2D = Two-dimensional 
3D = Three-dimensional 
CMR = Cardiac magnetic resonance imaging 
ICD = Implantable cardioverter defibrillator 
LV = Left ventricular 
LVEDV = Left ventricular end-diastolic volume 
LVEF = Left ventricular ejection fraction 
LVESV = Left ventricular end-systolic volume 
STEMI = ST-elevation myocardial infarction 







Assessment of left ventricular (LV) structure and function after ST-elevation myocardial 
infarction (STEMI) is key in identifying patients at high risk of further cardiovascular events 
[1,2]. Not only reduced LV ejection fraction (LVEF), but also increased LV mass and 
abnormal geometry pose an increased risk for morbidity and mortality after STEMI [3]. 
Although cardiovascular magnetic resonance imaging (CMR) is considered the gold standard 
imaging modality for assessment of cardiac structure and function [4], it currently has its 
disadvantages in terms of availability, time-consumption, and costs. 2D transthoracic 
echocardiography (2D TTE) is a widely available, bedside, time- and cost-effective 
alternative for CMR, and standard clinical care in patients hospitalized for STEMI [1,2]. 
 A meta-analysis on studies investigating the agreement between CMR and 2D TTE in the 
assessment of LV volumes and LVEF in patients and healthy volunteers show a large 
variation in bias and limits of agreement [5]. The individual studies have also lacked power to 
investigate whether patient characteristics might influence bias between imaging modalities. 
LV mass measurements are generally overlooked and have only been studied in subsets of 
patients [6,7]. We aimed to study the diagnostic accuracy of 2D TTE measurements compared 
with CMR in a large cohort of STEMI patients, and to investigate the potential effect of 
patient characteristics on bias between these imaging modalities. 
2. Material and methods 
2.1 Study population and design 
We studied 259 patients included in the Glycometabolic Intervention as adjunct to Primary 
percutaneous intervention in ST elevation myocardial infarction (GIPS-III) trial with available 
CMR and 2D TTE assessments at four months after hospitalization for STEMI. This study is 
a subanalysis of the GIPS-III trial, a single-center, randomized, placebo-controlled trial, 
recruiting 380 consecutive patients presenting with a first STEMI between January 1, 2011 
and May 26, 2013. Details on the GIPS-III trial have been reported previously [8,9]. In brief, 
380 patients were randomized to take either 500 mg metformin or placebo twice daily during 
a period of four months. Written informed consent was obtained in all participants. One 
patient withdrew informed consent, leaving 379 patients in the final study. Major exclusion 
criteria were known diabetes mellitus (as patients with diabetes mellitus already received 
metformin and could therefore not be randomized), previous myocardial infarction, 





dysfunction. The sample size of the study was determined for the primary efficacy measure, 
which was LVEF as measured by CMR at four months after the index event. Because no 
significant effect of metformin on LVEF was observed, and elaborate data collection 
including echocardiograms were obtained in most patients, the study was deemed suitable for 
further imaging substudies. 
2.2 Imaging procedures 
CMR is considered the reference standard. CMR was performed on a 3.0 Tesla whole-body 
scanner (Achieva, Philips), using a phased array cardiac receiver coil. During repeated breath-
holds, electrocardiogram-gated steady state free precession (SSFP) cine images were acquired 
in contiguous short-axis slices of 1 cm covering the entire LV. CMR scans (N=271) were 
assessed in an independent core laboratory by two experienced observers, using QMass 
(Medis, Leiden, the Netherlands). Endo- and epicardial borders were outlined in the end-
systolic and end-diastolic phases. LV end-diastolic volume (LVEDV), end-systolic volume 
(LVESV), and LV mass were measured in addition to LVEF, which was the primary outcome 
measure of the GIPS-III study. Cohort-specific CMR characteristics have been described and 
compared with reference values previously [10]. LVESV, LVEDV, LVEF, and LV mass were 
determined using the Simpson method of disk summation. LV mass was determined at the 
end-diastolic phase, excluding papillary muscles. Infarct size was defined as fraction of LV 
mass showing hyperenhancement on late gadolinium enhancement series, determined using 
the full width at half maximum (FWHM) technique [11]. 
 2D TTE is considered the index test. 2D TTE was performed on the same day as the CMR 
assessment, in left decubital position, using a Vivid 7 echo system (General Electric, Horton, 
Norway). Post-processing analyses were performed in an independent core laboratory 
(Groningen Imaging Core Laboratory, Groningen, the Netherlands) by four experienced 
observers, on an Echopac BT 10 (General Electric, Horton, Norway). LVEDV, LVESV, and 
LVEF were determined using the biplane summation of disks method (modified Simpson’s 
rule), which is the recommended method for 2D TTE volume calculations by the American 
Society of Echocardiography and the European Association of Cardiovascular Imaging [12]. 
The M-mode approach was not pursued, to avoid oblique sections of the ventricle. LV mass 
was estimated using the 2D linear dimension method [12,13].  
 Observers conducting CMR and 2D TTE post-processing analyses were blinded to all 





2.3 Statistical analysis 
Differences between CMR and 2D TTE measurements were tested for significance using a 
Wilcoxon matched-pairs signed-rank test. Bland-Altman analyses were used to assess limits 
of agreement between CMR and 2D TTE measurements [15]. Pairwise differences between 
CMR and 2D TTE-derived LVEDV, LVESV, and LV mass measurements were not normally 
distributed (P<0.05), as assessed by the Shapiro-Wilk test. The assumption of a normal 
distribution of pairwise differences between CMR and 2D TTE-derived LVEF measurements 
could not be disproven (P≥0.05) with the Shapiro-Wilk test. Bias and limits of agreement 
between LVEF measurements were assessed using the mean and 95% confidence interval of 
the differences, bias and limits of agreement between LVEDV, LVESV, and LV mass 




 percentiles of the 
differences. The correlation between 2D TTE and CMR LVEF measurements was quantified 
by calculating Pearson’s coefficient. We determined sensitivity, specificity, and positive and 
negative predicting value of 2D TTE to identify clinically relevant LVEF categories (≤35%, 
35-50%, ≥50%) as measured with CMR. We performed univariate and multivariable linear 
regression analyses of the absolute pairwise difference between CMR and 2D TTE 
measurements (CMR – 2D TTE), including the mean of the two measurements, age, and sex 
as covariates, to assess the effect of potential confounders or sources of bias between imaging 
modalities. In addition to age and sex, variables with significance level (P-value) <0.10 in 
univariate analyses were included in multivariable analysis. A P-value of 0.05 was considered 
significant, results were reported with standardized beta (Std. β), standardized error (SE) and 
P-value. Analyses were conducted with STATA/IC version 13.0 (StataCorp LP, College 
Station, Texas, USA). 
3. Results 
3.1 Patient characteristics  
A total of 299 patients (79%) participating in the GIPS-III trial underwent 2D TTE 
assessment, image quality was insufficient to determine LV mass in 9 subjects and to 
determine LV volumes in 38 subjects. CMR was performed in 275 patients (73%), image 
quality was insufficient to determine LV mass in 8 subjects and to determine LV volumes in 4 
subjects. CMR and 2D TTE measurements were available in 259 patients (61%), of which LV 
mass measurements in both imaging modalities were available in 255 patients and LV volume 





characteristics, as well as medication at discharge, are presented in Table 1. Median infarct 
size was 7.2% (2.6, 13.7) of LV mass.  
3.2 Differences between CMR and 2D TTE 
Differences between median values of same-day CMR and 2D TTE measurements were 
significant for all investigated variables. Median LVEDV was 189 ml (165, 226) measured by 
CMR, and 103 ml (88, 126) measured by 2D TTE (P<0.001). Median LVESV was 86 ml (66, 
107) measured by CMR, and 45 ml (37, 57) measured by 2D TTE (P<0.001). Median LVEF 
was 55.4% (49.5, 59.7) measured by CMR, and 56.4% (50.5, 61.3) measured by 2D TTE 
(P=0.004). Median LV mass was 102 g (86, 116) measured by CMR and 176 g (149, 201) 
measured by 2D TTE (P<0.001). Correlations between CMR and 2D TTE were very strong 
for LVESV measurements (r=0.84), and strong for LVEDV (r=0.75), LVEF (r=0.67), and LV 
mass (r=0.68) measurements. Scatter plots to demonstrate correlations are presented in Figure 
1 and Bland-Altman diagrams are presented in Figure 2. Pairwise difference (bias) and 95% 
limits of agreement between CMR and 2D TTE were +84 (37, 147) ml for LVEDV,  +39 (6, 
85) ml for LVESV, -1.1 (-14.7, 12.5) %  for LVEF, and -75 (-154, -14) g for LV mass. We 
observed a sensitivity of 25% and a specificity of 99% for 2D TTE to detect subjects with 
severely depressed LVEF (≤35%) as measured by CMR (N=8), resulting in a positive 
predictive value of 40% and a negative predictive value of 97% (Table 2). In multivariable 
linear regression analyses, we observed a significant effect of enzymatic infarct size on bias in 
LVESV and LVEF measurements (Table 3), suggesting lower LVESV and higher LVEF 
measurements in 2D TTE (P=0.029 and P=0.001 respectively). Age and sex were associated 
with bias in LVEDV and LV mass measurements, suggesting higher LVEDV and LV mass 
measurements in 2D TTE compared to CMR. We also observed a significant effect of heart 
rate at hospital admission on bias in LV volume measurements; a higher heart rate at 
admission was associated with relatively larger LVEDV and LVESV as measured with 2D 
TTE (P=0.006 and P=0.012 respectively). Systolic blood pressure was significantly associated 
with bias in LV mass measurements, indicating lower LV mass measurements with 2D TTE 
with increasing systolic blood pressure (P=0.024).  
4. Discussion 
In same-day 2D TTE and CMR assessments of a large STEMI cohort, we observed a 
substantial underestimation of LV volumes and overestimation of LV mass in 2D TTE 





agreement. We observed a low sensitivity of 2D TTE to identify subjects with LVEF ≤35% 
and LVEF <50%, as measured with CMR. Enzymatic infarct size, age, heart rate, and sex 
appeared to be sources of bias between 2D TTE and CMR measurements. As image 
acquisition and post-processing was performed in adherence to clinical recommendations 
[12,14], we believe the observed differences are universal in character. 
 In our study population, LV volumes were substantially underestimated by 2D TTE when 
compared to CMR. This corresponds with the results of a large meta-analysis of imaging 
studies including both patients and healthy controls (N=1579), in which LV volumes were 
underestimated (mean bias +33 ml in LVEDV and +16 ml in LVESV) to a lesser extent [5]. 
One large study including STEMI patients (N=150) investigated the agreement between 2D 
TTE and CMR in the assessment of LV volumes and LVEF, and found a slightly smaller bias 
in LV volumes compared with our study (+54 ml in LVEDV and +26 ml in LVESV) but with 
a similar range of agreement [16]. The observed bias in LVEF was similar compared to our 
presented study, but with a roughly 10% wider range in limits of agreement. The use of 3-
dimensional (3D) TTE appears to lower the absolute bias between TTE and CMR in 
estimating LV volumes but does not significantly improve the ranges of agreement [5,17]. In 
everyday clinical practice, limits of agreement might be wider than in a highly controlled core 
laboratory setting. For clinicians, it is important to stay aware that results from post-
processing of imaging assessments provide an estimation of the reality.  
 To further understand the observed differences, we believe we are the first to study the 
effect of potential confounders or sources of bias between 2D TTE and CMR measurements 
by applying linear regression analyses to find determinants of bias. We found that larger 
enzymatic infarct size (peak Troponin T) was associated with bias between 2D TTE and 
CMR-derived measurements of LVESV and LVEF, possibly resulting in an underestimation 
of LVESV and overestimation of LVEF by 2D TTE in patients with a large infarct size. This 
could partly explain why we observed a low sensitivity (52%) to detect LVEF <50% using 2D 
TTE and an even lower sensitivity (25%) to detect LVEF ≤35%, although this was only based 
on 8 patients. This resulted in a positive predictive value of 40% for 2D TTE to predict LVEF 
≤35%, and a positive predictive value of 54% to predict LVEF <50%. An accurate LVEF 
measurement is highly important as it is frequently used to determine clinical indications, e.g. 
for implantable cardioverter defibrillator (ICD) implantation (LVEF ≤35%), heart failure 
pharmacotherapy (LVEF ≤40%), or classification of heart failure patients in the new category 
of heart failure with mid-range ejection fraction (HFmrEF, 40-49%) [18-20]. In a cohort of 





CMR were considerably wider (44%) compared with this study [21]. A previous study 
investigating 35 subjects from which 25 were patients diagnosed with dilated cardiomyopathy 
observed that 11 (44%) differed in LVEF class (≤35%, 35-55%, >50%) when comparing 
biplane 2D TTE to CMR [22]. Another study found prognostic benefit of CMR over 2D TTE 
when using LVEF measurements to determine clinical indication for ICD implantation [23]. 
These results suggest that the Simpson’s biplane summation of disk method to determine 
LVEF in 2D TTE post-processing is more inaccurate in lower ranges of LVEF. Possible 
explanations are that the biplane method only visualizes part of the circumference of the left 
ventricle, possibly not accounting well enough for regional wall motion abnormalities, and 
that imaging planes are difficult to recognize in diseased ventricles. These results support the 
use of CMR in patients with large myocardial infarctions for clinical decision-making around 
ICD implantation and pharmacologic treatment, and for accurate classification of heart failure 
categories in clinical trials. An alternative would be to define imaging modality specific 
thresholds for treatment, which might be set higher in case of a more accurate CMR 
assessment. 
 Contrary to LV volumes, we found a large overestimation of LV mass, as determined by 
the linear dimension method on 2D TTE. Few studies have investigated the agreement of 2D 
TTE with CMR in assessing LV mass. It has been studied in patients with cardiomyopathy 
(N=104) and patients with hypertension (N=40), which both observed a bias of approximately 
+30%, similar to our results [6,7]. Both the 2D TTE linear dimension method and the SSFP-
CMR short axis segmentation method have been validated against ex-vivo LV mass 
measurements of human hearts [13,24]. Important to note is that the validation study for CMR 
was performed using the Automatic Thresholding with Manual Trimming (ATMT) method 
which included trabecularization and papillary muscle mass [24]. CMR measurements of LV 
mass in the GIPS-III study excluded trabecularization and papillary muscle mass, possibly 
leading to underestimation of LV mass. The linear dimension method is commonly used in 
clinical practice, as recommended by the American Society of Echocardiography [12]. The 
main advantages of the linear method are that it is fast, has demonstrated prognostic value, 
and that reference values are well defined. The main disadvantage is that the linear method is 
based on the simplified assumption of the LV as a prolate ellipsoid of revolution, and does not 
account well for geometric variation [25]. STEMI survivors are known to experience 
geometric changes of the LV leading to a more spherical shape, which could account for some 
of the overestimation [26]. We believe that effort should be made to level measurement 





thresholds. Improving the accuracy and reproducibility of TTE in estimating LV mass can be 
achieved by the more laborious manual or semiautomated delineation of endo- and epicardial 
borders, and by using contrast-enhanced 2D TTE or 3D TTE, of which the latter has been 
validated against CMR in a large cohort [27,28].  
 We observed a very strong association between female sex and bias between 2D TTE and 
CMR in LV mass measurements. Females are known to have smaller LV dimensions and a 
lower mass to volume ratio (or relative wall thickness) [29]. This could imply that the linear 
dimension method does not account well for differences in LV geometry between genders, 
although the original discovery cohort did include more females than males [13]. Systolic 
blood pressure has also been linked to geometric (concentric) remodeling [30,31]. Future 
considerations could be to improve the linear dimension technique by studying a wider range 
of patients with and without LV hypertrophy in both sexes.  
 Interestingly, body mass index was not associated with bias in LV mass, LV volumes, or 
LVEF, although it is known to negatively affect TTE image quality [32]. Even though it 
affects reliability of measurements due to reducing visibility of endo- and epicardial borders, 
it appears to not lead to a structural under- or overestimation of 2D TTE measurements.  
 In clinical practice, LVEF remains widely used as a biomarker for risk stratification. 
However, it is only moderately reproducible because of limitations such as its reliance on 
geometric assumptions to determine LV volumes and dependency on loading conditions and 
heart rate [33]. Myocardial deformation parameters such as strain and strain rate provide 
added value in predicting adverse outcome after myocardial infarction and should be 
considered in the future as an alternative or addition to the use of LVEF as major risk 
stratification parameter [34]. Other CMR-specific parameters that could provide important 
prognostic information after STEMI include myocardial salvage index, microvascular 
obstruction, and myocardial hemorrhage [35]. Future studies will have to determine which 
imaging parameters can best discriminate between patients needing regular care and high-risk 
patients requiring intensive monitoring and treatment.  
4.1 Limitations 
Results could have been influenced by exclusion criteria of the GIPS-III study such as 
previous STEMI or known diabetes. In this substudy, we excluded patients who did not 
undergo CMR and/or 2D TTE assessment. Excluded subjects were older, more often female, 
and had a smaller infarct size, resulting in a selection bias and limiting generalizability. LV 





of the included subjects. Median infarct size (7% of LV mass) was relatively small, which 
might have affected the results. Subjects generally had a well preserved LVEF, only 8 
subjects (3%) had a clinical indication for ICD implantation (LVEF ≤35% as measured with 
CMR).  
5. Conclusions 
Our findings confirm that LV volumes are substantially underestimated and LV mass is 
overestimated by 2D TTE compared to CMR, with wide ranges of agreement even in the 
presence of reasonable correlations. Our data suggests that age, gender, heart rate, and infarct 
size are sources of bias between imaging modalities. 2D TTE appears to have a low 
sensitivity to detect depressed LVEF, and increasing enzymatic infarct size leads to 
overestimation of 2D TTE measurements.  
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Figure 1: Scatter plots demonstrating linear correlations between CMR-derived measurements (y-axis) and 2D TTE-derived 
measurements (x-axis) of (A) LVEDV, (B) LVESV, (C) LVEF, and (D) LV mass 
CMR, cardiovascular magnetic resonance imaging; 2D TTE, 2-dimensional transthoracic echocardiography; LVEDV, left ventricular end-






Figure 2: Bland-Altman diagrams demonstrating bias and 95% limits of agreement in mean values of (A) LVEDV, (B) LVESV, (C) 
LVEF, and (D) LV mass, as measured by CMR and 2D TTE 
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction; LV, left 





Table 1: Patient characteristics during hospital admission for STEMI 
Characteristic 
CMR and 2D TTE 
available (N=259) 




Randomization treatment 130 (50.2) 61 (50.8) 0.91 
Age, yrs 57.6 (11.6) 61.3 (11.4) 0.004 
Sex, % female 52 (20.1) 43 (35.8) <0.001 
Body mass index, kg/m² 26.9 (3.5) 27.1 (4.4) 0.56 
Race/ethnicity, % Caucasian 246 (95.0) 119 (99.2) 0.088 
Hypertension 70 (27.0) 42 (35.0) 0.11 
Dyslipidemia 158 (61.0) 81 (67.5) 0.22 
Current smoking 131 (50.6) 78 (65.0) 0.009 
Systolic blood pressure, mmHg 132.6 (21.8) 138.2 (26.1) 0.031 
Diastolic blood pressure, mmHg 84.2 (14.4) 84.7 (15.1) 0.72 
Heart rate, bpm 75.5 (15.9) 76.1 (17.3) 0.76 
Single vessel disease 186 (71.8) 72 (60.0) 0.022 
Infarct-related artery   0.48 
LAD 105 (40.5) 41 (34.2)  
LCX 43 (16.6) 21 (17.5)  
RCA 111 (42.9) 58 (48.3)  





Infarct-related artery TIMI flow <3 post-PCI 17 (6.6) 17 (14.2) 0.016 
Myocardial blush grade 0-1 23 (8.9) 16 (13.3) 0.18 
HbA1c 5.8 (5.6, 6.0) 5.8 (5.6, 6.1) 0.19 
LDL cholesterol, mmol/L 3.9 (1.0) 3.8 (1.1) 0.72 
eGFR, ml/min 97.4 (15.0) 94.3 (16.5) 0.068 
Peak CK-MB, U/L 166 (78, 328) 122 (53, 310) 0.15 
Peak Troponin T, ng/L 3121 (1304, 6365) 2084 (769, 5528) 0.099 
Medication at discharge    
Aspirin 255 (98.5) 112 (93.3) 0.008 
Statin 259 (100) 118 (98.3) 0.037 
Beta-blocker 248 (95.8) 114 (95) 0.74 
ACE-inhibitor or Angiotensin II receptor blocker 206 (79.5) 95 (79.2) 0.93 
Aldosterone receptor antagonist 26 (10) 12 (10) 0.99 
Diuretic 3 (1.2) 9 (7.5) 0.001 
CMR, cardiovascular magnetic resonance imaging; 2D TTE, 2-dimensional transthoracic echocardiography; IQR, interquartile range; PCI, 
percutaneous coronary intervention; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; TIMI, 
Thrombolysis in Myocardial Infarction; HbA1c, glycated hemoglobin; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate; 
CK, creatine kinase.  






Table 2: Sensitivity and specificity analyses of 2D TTE-derived LVEF 
  LVEF category (TTE)  
  ≤35% 35-50% ≥50% Total 
LVEF category (CMR) ≤35% 2 (25%) 5 (62.5%) 1 (12.5%) 8 (100%) 
35-50% 3 (5.8%) 27 (51.9%) 22 (42.3%) 52 (100%) 
≥50% 0 (0%) 18 (10.2%) 158 (89.8%) 176 (100%) 
Total  5 50 181 236 
Sensitivity  25% 52% 90%  
Specificity  99% 88% 62%  
Positive predictive value  40% 54% 87%  
Negative predictive value  97% 87% 67%  





Table 3: Regression of absolute difference (bias) between CMR and 2D TTE measurements; effect of potential confounders 


















Age -0.17±0.06 0.004 -0.20±0.06 0.001 -0.05±0.05 0.32 -0.09±0.05 0.09 -0.10±0.06 0.11 -0.07±0.07 0.31 -0.10±0.04 0.030 -0.10±0.04 0.027 
Female sex -0.10±0.06 0.10 -0.13±0.06 0.039 0.00±0.05 0.99 -0.04±0.05 0.49 -0.08±0.07 0.26 -0.06±0.07 0.39 -0.19±0.05 <0.001 -0.20±0.05 <0.001 
Randomization treatment 0.01±0.06 0.85   0.02±0.05 0.65   0.00±0.07 0.96   0.00±0.05 0.98   
Body mass index 0.01±0.06 0.92   0.02±0.05 0.35   0.04±0.07 0.52   -0.06±0.05 0.21   
Caucasian ethnicity 0.09±0.06 0.16   0.02±0.05 0.76   0.11±0.07 0.12   -0.01±0.04 0.80   
Hypertension 0.01±0.06 0.88   -0.01±0.05 0.80   0.02±0.07 0.75   0.07±0.05 0.17   
Dyslipidemia 0.00±0.06 0.99   0.01±0.05 0.85   -0.05±0.07 0.45   -0.03±0.05 0.51   
Current smoking 0.00±0.07 0.98   0.02±0.06 0.73   -0.01±0.07 0.87   0.10±0.05 0.059   
Systolic blood pressure 0.03±0.06 0.62   0.00±0.05 0.98   0.01±0.06 0.84   0.10±0.05 0.024 0.10±0.05 0.024 
Diastolic blood pressure -0.02±0.06 0.76   -0.03±0.05 0.51   0.06±0.07 0.39   0.10±0.05 0.037   
Heart rate -0.18±0.06 0.003 -0.18±0.06 0.004 -0.13±0.05 0.012 -0.13±0.05 0.016 0.05±0.07 0.46   0.05±0.05 0.31   




                
-0.02±0.06 0.74   -0.03±0.05 0.57   0.01±0.07 0.83   0.03±0.04 0.47   
-0.03±0.06 0.65   -0.07±0.05 0.20   0.10±0.07 0.14   -0.06±0.05 0.18   
TIMI flow 0 pre-PCI 0.13±0.06 0.032   0.10±0.05 0.049   -0.07±0.07 0.27   -0.04±0.05 0.33   
TIMI flow <3 post-PCI 0.13±0.06 0.030 0.12±0.06 0.033 0.09±0.05 0.058   -0.04±0.06 0.57   -0.07±0.05 0.15   
Myocardial blush grade 0-1 0.04±0.06 0.53   0.04±0.05 0.40   -0.07±0.06 0.29   -0.03±0.05 0.56   
Peak CK-MB 0.03±0.07 0.62   0.11±0.06 0.066   -0.27±0.08 0.001   0.02±0.05 0.71   





2D TTE, 2-dimensional transthoracic echocardiography; CMR, cardiovascular magnetic resonance imaging; PCI, percutaneous coronary intervention; LAD, 
left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; TIMI, Thrombolysis in Myocardial Infarction; CK-MB, myocardial 
band of creatine kinase. 
 
